FRENCH ANNEX STOCK OPTION AGREEMENT (QUALIFIED STOCK OPTIONS)French Annex Stock Option Agreement • November 15th, 2005 • Idm Pharma, Inc. • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, IDM Pharma, Inc. (the “Company”) has granted you an option under the French Annex to its 2000 Stock Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
FOURTH AMENDMENT of the LICENSE AGREEMENTLicense Agreement • November 15th, 2005 • Idm Pharma, Inc. • Pharmaceutical preparations • California
This Fourth Amendment of the License Agreement is made this 28th day of September 2005 (the “Fourth Amendment”) by and between IDM Pharma, Inc. (formerly Epimmune Inc. (hereinafter referred to as “Epimmune”)), having an office and a place of business at 5820 Nancy Ridge Drive, San Diego, California 92121 U.S.A (hereinafter referred to as “IDMI”), and Innogenetics N.V., having an office and a place of business at Technologiepark 6, B-9052 Ghent, Belgium (hereinafter referred to as “INNX”), to amend the License Agreement dated July 9, 2001 between IDMI and INNX (the “Agreement”) as amended by a First Amendment of the License Agreement, dated October 16, 2002 (the “First Amendment”), a Second Amendment of the License Agreement, dated March 15, 2004 (the “Second Amendment”) and a Third Amendment of the License Agreement, dated March 29, 2004 (the “Third Amendment”).
French Participants Deferred Issuance Restricted Stock Bonus AgreementRestricted Stock Bonus Agreement • November 15th, 2005 • Idm Pharma, Inc. • Pharmaceutical preparations
Pursuant to the Deferred Issuance Restricted Stock Bonus Grant Notice (“Grant Notice”) and this Deferred Issuance Restricted Stock Bonus Agreement (collectively, the “Award”) and in consideration of your past services, IDM Pharma, Inc. (the “Company”) has awarded you a deferred issuance restricted stock bonus under its 2000 Stock Plan (the “Plan”) for the number of shares of the Company’s Common Stock subject to the Award as indicated in the Grant Notice. Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award (the "Effective Date”). Defined terms not explicitly defined in this Deferred Issuance Restricted Stock Bonus Agreement but defined in the Plan shall have the same definitions as in the Plan.
FOURTH AMENDMENT of the COLLABORATION AGREEMENTCollaboration Agreement • November 15th, 2005 • Idm Pharma, Inc. • Pharmaceutical preparations • California
This Fourth Amendment of the Collaboration Agreement is made this 28th day of September 2005 (the “Fourth Amendment”) by and between IDM Pharma, Inc. (formerly Epimmune Inc. (hereinafter referred to as “Epimmune”)), having an office and a place of business at 5820 Nancy Ridge Drive, San Diego, California 92121 U.S.A (hereinafter referred to as “IDMI”), and Innogenetics N.V., having an office and a place of business at Technologiepark 6, B-9052 Ghent, Belgium (hereinafter referred to as “INNX”) to amend the Collaboration Agreement dated July 9, 2001 between IDMI and INNX (the “Agreement”), as amended by a First Amendment of the Collaboration Agreement, dated October 16, 2002 (the “First Amendment”), a Second Amendment of the Collaboration Agreement, dated October 7, 2003 (the “Second Amendment”) and a Third Amendment of the Collaboration Agreement, dated March 16, 2004 (the “Third Amendment”).
THIRD AMENDMENT TO THE AGREEMENT ENTITLED “LICENSE AGREEMENT to Hepatitis Virus Immunology and Immunotherapy” ENTERED INTO SEPTEMBER 23, 1991 BETWEEN THE SCRIPPS RESEARCH INSTITUTE AND CYTEL CORPORATIONLicense Agreement • November 15th, 2005 • Idm Pharma, Inc. • Pharmaceutical preparations • California
This Third Amendment to the agreement entitled “License Agreement to Hepatitis Virus Immunology and Immunotherapy” (the “Third Amendment”) is entered into and made effective as of July 30, 2005 (the “Amendment Effective Date”) by and between The Scripps Research Institute, a California nonprofit public benefit corporation (“TSRI”) located at 10550 North Torrey Pines Road, La Jolla, California 92037, and Epimmune Inc. (“Licensee”), a Delaware corporation located at 5820 Nancy Ridge Drive, San Diego, California, 92121, with respect to the facts set forth below.
